There are currently 399 ongoing clinical trials involving Hepatitis B
Of the 399 trials,146 trials are in Phase IV
Furthermore, 131 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Hepatitis B, Infectious Disease. Asia-Pacific, Europe, and North America are some of the prominent regions engaged in Hepatitis B-related drug trials.
Hepatitis B related clinical trial sponsors
Sun Yat-Sen University Hospital 3, Beijing Ditan Hospital, Beijing You An Hospital Capital Medical University, and Huashan Hospital are some of the notable clinical trial sponsors involved in Hepatitis B. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Hepatitis B
Tenofovir alafenamide (Vemlidy), Entecavir (Baraclude) and Thymalfasin (Zadaxin) are among the key marketed drugs involving Hepatitis B.
Tenofovir alafenamide (Vemlidy) acts as an anti-viral agent. It functions via Reverse Transcriptase (EC 2.7.7.49) Inhibitor mechanism of action. It is formulated as film coated tablets, coated tablets for oral route of administration. Vemlidy is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease, and in adolescents aged 12 years and older. Vemlidy was first approved in 2016 and is marketed globally including the US, the UK, Australia, France, and Germany by Gilead Sciences Inc and its subsidiaries.
Entecavir (Baraclude) is a guanosine nucleoside analogue which has selective activity against HBV. It functions via Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Inhibitor mechanism of action. It is formulated as film-coated tablets and solution for oral route of administration. Baraclude is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Baraclude was first approved in 2005 and is marketed globally including the US, the UK, Australia, France, and Germany by Bristol-Myers Squibb Co and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward